News

Anxiety and Depression in PAH Patients Could Be Eased with Psychosocial Therapies, Review Study Suggests

Non-pharmacological approaches such as relaxation training, slow breathing, and cognitive behavioral therapy could help lessen anxiety and depression in patients with pulmonary arterial hypertension (PAH), according to a review study. The research, “Anxiety and depression in patients with pulmonary hypertension: impact and management challenges,” was published…

Morphogen-IX Announces MGX292 as Treatment Candidate for PAH

Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies that have shown the potential of MGX292, a signaling protein analogue, as a safe and effective therapy for PAH.